Recurrent Myelodysplastic/Myeloproliferative Neoplasm Clinical Trials

5 clinical trials for Recurrent Myelodysplastic/Myeloproliferative Neoplasm across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms — RECRUITING · PHASE1
• Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm — RECRUITING · PHASE1
• Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia — RECRUITING · PHASE1
• Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy — RECRUITING · PHASE1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial — TERMINATED · PHASE1

Refine this search